Private & confidential
Dr. Hou Jinlin
Chinese name: 侯金林
Professor, Chief Physician, Doctoral Supervisor . Infectious Diseases & Hepatology
Professor Hou Jinlin is Director of Infectious Diseases at Nanfang Hospital of Southern Medical University and Director of the Guangdong Institute of Liver Diseases. A National Science Fund for Distinguished Young Scholars awardee, he is a leading authority on viral hepatitis and led trials of finite-course functional cure for chronic hepatitis B.
Dr. Hou Jinlin
500+
Published papers
2
National Science and Technology Progress Awards (second class)
7
Consecutive years as a Most Cited Chinese Researcher
About Dr. Hou Jinlin
Professor Hou Jinlin is Director of Infectious Diseases at Nanfang Hospital of Southern Medical University, Director of the Guangdong Institute of Liver Diseases and a former president of the Asian Pacific Association for the Study of the Liver. A National Science Fund for Distinguished Young Scholars awardee, he has devoted his career to viral hepatitis and liver disease, with particular expertise in the diagnosis and treatment of complex chronic hepatitis B. He developed an individualised antiviral treatment roadmap and led international trials of finite-course regimens that can achieve functional cure of chronic hepatitis B. He has published widely in leading journals and received the Guangdong May First Labour Medal.
1、Director of Infectious Diseases at Nanfang Hospital of Southern Medical University
2、Director of the Guangdong Institute of Liver Diseases
3、Former President of the Asian Pacific Association for the Study of the Liver
4、Former Chairman of the Chinese Society of Infectious Diseases
5、Recipient of the National Science Fund for Distinguished Young Scholars
6、Named a National Health System Outstanding Young and Middle-aged Expert and a Guangdong Good Doctor
Dr. Hou Jinlin ’s Three Key Areas of Expertise
Three areas of focused expertise, each supported by a deep subspecialty team, high case volumes and an English-speaking care pathway coordinated by Orisene.
Chronic hepatitis B
He diagnoses and treats chronic hepatitis B with individualised antiviral therapy and long-term monitoring, aiming for viral suppression and functional cure and reducing the risks of cirrhosis and liver cancer in patients living with this common chronic viral infection in routine clinical practice.
Hepatitis C and fatty liver disease
He manages chronic hepatitis C and fatty liver disease with direct-acting antiviral therapy, metabolic assessment and lifestyle guidance, working to cure the infection and prevent progression to cirrhosis and liver cancer for patients with these increasingly common liver conditions in routine clinical practice.
Liver cirrhosis and liver failure
He treats liver cirrhosis and acute-on-chronic liver failure with antiviral therapy, intensive medical support and complication management, integrating close monitoring to control the underlying cause, protect residual liver function and improve survival for patients with these severe, life-threatening liver diseases.
More：hepatitis B mother-to-child transmission——prevention; autoimmune liver disease——diagnosis; drug-induced liver injury——management; hepatocellular carcinoma——surveillance; fever of unknown origin——assessment
Selected cases, research & publications
Representative work drawn from documented clinical treatments, publicly indexed literature, and hospital project records, reflecting the depth of this physician's hands-on expertise and academic rigor.
1. Xalnesiran with or without an Immunomodulator for Chronic Hepatitis B (Piranga Trial)
This phase two multicenter randomized trial led by Hou Jinlin evaluated xalnesiran, a small interfering RNA, with or without immunomodulators in one hundred fifty nine adults with chronic hepatitis B. The xalnesiran plus pegylated interferon group achieved twenty three percent hepatitis B surface antigen loss twenty four weeks after treatment, advancing combination strategies toward functional cure.
Related link: https://doi.org/10.1056/NEJMoa2405485
2. Bepirovirsen B-Well Trials for Functional Cure of Chronic Hepatitis B
The international B-Well one and B-Well two phase three trials, with Hou Jinlin as first author, evaluated bepirovirsen, an antisense oligonucleotide, in chronic hepatitis B. Bepirovirsen achieved functional cure rates of about twenty percent versus none with placebo, supporting a potential finite-course treatment that could allow many patients to stop lifelong nucleoside analogue therapy.
Related link: https://doi.org/10.1056/NEJMoa2515131
3. SHIELD App for Preventing Mother-to-Child Hepatitis B Transmission
Hou Jinlin’s team developed the SHIELD mobile application to block mother-to-child transmission of hepatitis B, enrolling more than thirty thousand pregnant women with chronic hepatitis B. The digital platform standardises screening, antiviral prophylaxis and newborn immunisation, dramatically reducing infant infection and supporting China’s progress toward eliminating hepatitis B transmission in newborns.
Related link: https://www.nature.com/articles/d42473-021-00530-8
4. GAAD Algorithmic Score for Early Detection of Hepatitis B Related Liver Cancer
Hou Jinlin contributed to the GAAD score, a blood-based algorithm combining gender, age, alpha fetoprotein and PIVKA-II, for early detection of hepatocellular carcinoma in patients with chronic hepatitis B and cirrhosis. The model improves early diagnosis of liver cancer in high-risk patients, enabling timely curative therapy and better long-term survival outcomes.
Related link: https://www.nfyy.com/wap/ks/zk/grnk/doctor_5953.html
5. AHB-137 Antisense Oligonucleotide and Durable Functional Cure
Hou Jinlin presented long-term follow-up data of AHB-137, an investigational antisense oligonucleotide for chronic hepatitis B, at The Liver Meeting 2026. The AB-10-8004 study reported durability of functional cure in treatment-naive patients and in nucleoside analogue treated patients, offering evidence for finite-duration regimens aimed at curing chronic hepatitis B.
6. HRS-5635 Phase Three Trial in Chronic Hepatitis B (NCT07606950)
Hou Jinlin serves as principal investigator of a phase three clinical trial of HRS-5635 for chronic hepatitis B at Nanfang Hospital. The study evaluates a novel agent for virologic suppression and hepatitis B surface antigen reduction, aiming to expand effective treatment options and improve functional cure rates for patients living with chronic hepatitis B infection.
Related link: https://clinicaltrials.gov/study/NCT07606950
Where Dr. Hou Jinlin practices
Nanfang Hospital, Southern Medical University
Chinese name: 南方医科大学南方医院
Nanfang Hospital, founded in 1941 as a wartime rear hospital and now a national regional medical center of Southern Medical University, is a Grade-A tertiary hospital holding 5 national key disciplines, 17 national key specialties and a nationally leading nephrology program.
Since 1941
85 years of care
2,225
Licensed beds
17
National key specialties
3.32 million (2021)
Licensed beds
Appointments with this physician are booked through official hospital channels only, coordinated end-to-end by Orisene.
Why patients travel to China for treatment
Six reasons international patients now put China on their shortlist — from internationally aligned clinical capability to the policy channels that make treatment here genuinely reachable.
Clinical capability at international standard
Chinese hospitals deliver internationally aligned protocols, performing vast volumes of advanced robotic, minimally invasive, and complex transplant surgeries annually. This massive clinical data and highly specialized workforce ensure world-class outcomes, even for rare and complex cases.
Diagnostics and treatment in days, not months
A full medical workup that typically means months of waiting elsewhere is completed in China within 48–72 hours. Imaging, labs, and multidisciplinary consultations are integrated into a single visit, allowing treatment to commence immediately.
Transparent, itemised pricing
Chinese healthcare offers legally binding, itemised cost estimates before treatment begins, eliminating hidden fees or surprise billing. Due to national centralized procurement, total expenses remain 40–70% lower than comparable care in Western Europe or North America.
Policy channels that open the door
China facilitates access through 240-hour visa-free transit and dedicated medical visa routes. Policies like the Greater Bay Area drug pathway and Boao Lecheng’s pilot zone allow designated hospitals to administer innovative therapies not yet globally approved.
Consulting this physician, step by step
From the first message to the follow-up after you fly home, one coordinator, no paperwork on your side.
01
Day 0
- Share your storyA private consultation with an Orisene advisor, by message, phone or video. Send medical records in any language. Nothing is shared with the hospital yet.
02
Days 1–3
- Records review & matchingOrisene translates and presents your case to the right specialist. The hospital returns a tailored care plan, with costs itemised once that plan is confirmed.
03
Days 3–7
- Your consultationAppointments are booked through official hospital channels only. Your navigator accompanies every visit with real-time interpretation, so you can focus on one thing: being cared for.
04
After you fly home
- Reports & follow-upTranslated reports and prescriptions delivered within days, remote follow-up coordination with your physicians at home, and a standing line to your navigator.
Orisene offers English and multilingual services, a professional medical interpreter at every consultation, plus translation of your records, reports and prescriptions.
Ready to plan your consultation with Dr. Hou Jinlin?
Send your records in any language. An Orisene advisor will reply within 2 hours, present your case to the right specialist, and return a tailored care plan with itemised costs, before anything is booked. Simple. Private. Efficient.
Information Sources
This physician profile is compiled by the Orisene team from publicly available online sources and verified at the time of publication. Details may change, and physician availability is confirmed at the time of booking.
- Nanfang Hospital Official Expert Page (Infectious Diseases): https://www.nfyy.com/wap/ks/zk/grnk/doctor_5953.html
- PubMed Author Records (hepatitis B): https://pubmed.ncbi.nlm.nih.gov/42206582/
Disclaimer: This information is for general educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider for personal medical guidance.
Mention of any specific product, brand, or manufacturer is for informational purposes only and does not constitute an endorsement or recommendation by Dr. Hou Jinlin.